Q2 2025
Released Aug 7, 2025, after the close
10-Q filed Aug 7, 2025, 38 days after period end · 0001641172-25-022596
Q2 2025 · 10-Q
Revenue$4.42M$4.42M +35.9% vs Q2 2024−9.4% vs Q1 2025
Net Income$237.00K$237.00K N/M vs Q2 2024−57.5% vs Q1 2025
EPS Diluted$0.02$0.02 N/M vs Q2 2024−60.0% vs Q1 2025
Gross Profit$2,795,000+46.2%
Operating Income$248,000N/M
Operating Cash Flowderived$994,000N/M
Margins · derived
Gross margin63.2%+4.5 pt vs Q2 2024
Operating margin5.6%+15.4 pt vs Q2 2024
Net margin5.4%+14.3 pt vs Q2 2024
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | $4.42M | $3.25M | $3.55M | $2.85M |
| Net Income | $237.00K | -$289.00K | -$433.00K | -$1.14M |
| EPS Diluted | $0.02 | -$0.03 | -$0.04 | -$0.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nephros Inc · CIK 1196298 · Engraved from SEC EDGAR